Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01703364 | Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL | completed | Phase 1 / Phase 2 | 12 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | May 26, 2016 | clinicaltrials |
| NCT01034553 | Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 26 | Mayo ClinicOTHER | 1 | May 25, 2016 | clinicaltrials |
| NCT01562990 | Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse | completed | Phase 1 / Phase 2 | 11 | The Lymphoma Academic Research OrganisationOTHER | 2 | May 23, 2016 | clinicaltrials |
| NCT01376401 | Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 60 | PETHEMA FoundationOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT00406978 | Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients(MPTD) | completed | Phase 1 / Phase 2 | 24 | Silvio AimeOTHER | 1 | May 10, 2016 | clinicaltrials |
| NCT00961467 | RMPT for Relapsed/Refractory Multiple Myeloma(RMPT) | completed | Phase 2 | 44 | Fondazione EMN Italy OnlusOTHER | 1 | May 10, 2016 | clinicaltrials |
| NCT02533401 | A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 34 | Hoffmann-La RocheINDUSTRY | 2 | May 2, 2016 | clinicaltrials |
| NCT00833833 | MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 259 | Celgene CorporationINDUSTRY | 2 | Apr 27, 2016 | clinicaltrials |
| NCT00831597 | Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(904) | completed | Phase 2 | 61 | PharmatechINDUSTRY | 1 | Apr 19, 2016 | clinicaltrials |
| NCT00250926 | Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 8, 2016 | clinicaltrials |
| NCT00532129 | A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia. | completed | Phase 2 | 100 | Hoffmann-La RocheINDUSTRY | 1 | Apr 6, 2016 | clinicaltrials |
| NCT01394354 | Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)(VBDD) | completed | Phase 1 / Phase 2 | 34 | University Hospital FreiburgOTHER | 1 | Apr 6, 2016 | clinicaltrials |
| NCT01450215 | Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma | completed | Phase 2 | 62 | Karolinska University HospitalOTHER | 1 | Mar 25, 2016 | clinicaltrials |
| NCT00999830 | Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma(REMYKIR) | completed | Phase 2 | 27 | Innate PharmaINDUSTRY | 1 | Mar 24, 2016 | clinicaltrials |
| NCT02412267 | Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)(DLBL) | completed | Phase 2 | 17 | National Cancer Centre, SingaporeOTHER | 1 | Mar 23, 2016 | clinicaltrials |
| NCT01457144 | Study of Mantle Cell Lymphoma Treatment by RiBVD(RIBVD) | completed | Phase 2 | 76 | French Innovative Leukemia OrganisationOTHER | 1 | Mar 16, 2016 | clinicaltrials |
| NCT00618969 | Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors | completed | Phase 2 | 2 | University of ArizonaOTHER | 1 | Mar 3, 2016 | clinicaltrials |
| NCT01523860 | Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma(FLE09) | completed | Phase 2 | 76 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Mar 1, 2016 | clinicaltrials |
| NCT00123773 | Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence | completed | Phase 2 | 1,075 | AHS Cancer Control AlbertaOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT00975975 | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | completed | Phase 2 | 17 | Indiana UniversityOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01352338 | Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)(REPEAT) | completed | Phase 1 / Phase 2 | 82 | UMC UtrechtOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01413568 | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 38 | Polyphor Ltd.INDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01094548 | Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy | completed | Phase 2 | 34 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Feb 22, 2016 | clinicaltrials |
| NCT00280241 | Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia | completed | Phase 2 | 65 | University of PittsburghOTHER | 1 | Feb 4, 2016 | clinicaltrials |
| NCT00438880 | Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 38 | Mayo ClinicOTHER | 1 | Feb 4, 2016 | clinicaltrials |
| NCT01419691 | Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 15 | University of Kansas Medical CenterOTHER | 1 | Jan 18, 2016 | clinicaltrials |
| NCT00381004 | FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT01314014 | Imexon for Relapsed Follicular and Aggressive Lymphomas(ULYM11011) | completed | Phase 2 | 22 | University of RochesterOTHER | 1 | Jan 6, 2016 | clinicaltrials |
| NCT00453102 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma | completed | Phase 2 | 18 | University of MiamiOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT00023764 | Bortezomib in Treating Patients With Lymphoproliferative Disorders | completed | Phase 2 | 103 | National Cancer Institute (NCI)NIH | 1 | Dec 8, 2015 | clinicaltrials |
| NCT00514371 | A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma(TIME-2) | completed | Phase 2 / Phase 3 | 22 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 7, 2015 | clinicaltrials |
| NCT01123356 | Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab | completed | Phase 2 | 21 | Medical University of South CarolinaOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00448019 | FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 2, 2015 | clinicaltrials |
| NCT01187303 | Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) | completed | Phase 2 | 28 | University of CologneOTHER | 1 | Nov 2, 2015 | clinicaltrials |
| NCT01521533 | NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma | completed | Phase 2 | 28 | TME Pharma AGINDUSTRY | 4 | Oct 6, 2015 | clinicaltrials |
| NCT00103558 | Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 / Phase 2 | 31 | BiogenINDUSTRY | 1 | Oct 2, 2015 | clinicaltrials |
| NCT00435084 | A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL | completed | Phase 1 / Phase 2 | 10 | Valerio TherapeuticsINDUSTRY | 1 | Sep 23, 2015 | clinicaltrials |
| NCT00609869 | Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab | completed | Phase 2 | 29 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT01084837 | Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure(RENVEL) | completed | Phase 2 | 60 | PETHEMA FoundationOTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT00131937 | Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2015 | clinicaltrials |
| NCT00915408 | A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma(CRD) | completed | Phase 1 / Phase 2 | 32 | King's College Hospital NHS TrustOTHER | 1 | Sep 2, 2015 | clinicaltrials |
| NCT01236391 | Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)(PCYC-1104-CA) | completed | Phase 2 | 115 | Pharmacyclics LLC.INDUSTRY | 4 | Aug 28, 2015 | clinicaltrials |
| NCT00759603 | Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 27, 2015 | clinicaltrials |
| NCT01085214 | AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2015 | clinicaltrials |
| NCT02221479 | Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma | completed | Phase 2 | 14 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 4, 2015 | clinicaltrials |
| NCT00131261 | Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma | completed | Phase 2 | 25 | Valerio TherapeuticsINDUSTRY | 4 | Jul 8, 2015 | clinicaltrials |
| NCT00431873 | A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia | completed | Phase 2 | 21 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jul 1, 2015 | clinicaltrials |
| NCT01217749 | Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL(PCYC-1109-CA) | completed | Phase 1 / Phase 2 | 71 | Pharmacyclics LLC.INDUSTRY | 1 | Jun 25, 2015 | clinicaltrials |
| NCT00083382 | Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide | completed | Phase 2 | 83 | University of ArkansasOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT01531998 | Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 19, 2015 | clinicaltrials |
Data updated 23 days agoSource updated May 26, 2016source: clinicaltrials